Coherus Oncology, Inc. (CHRS) Debt Components
- 2026-06-30: Debt Instrument, Repurchase AmountUSD (m); Debt Instrument, Interest Rate, Effective Percentagepure 2.10%; Debt Instrument, Interest Rate During Periodpure (m); Debt Instrument, Redemption Price, Percentagepure (m).
- 2026-03-31: Debt Instrument, Repurchase AmountUSD (m); Debt Instrument, Interest Rate, Effective Percentagepure 2.10%; Debt Instrument, Interest Rate During Periodpure (m); Debt Instrument, Redemption Price, Percentagepure (m).
- 2025-12-31: Debt Instrument, Repurchase AmountUSD (m); Debt Instrument, Interest Rate, Effective Percentagepure (m); Debt Instrument, Interest Rate During Periodpure 3 month · 12.00%; Debt Instrument, Redemption Price, Percentagepure (m).
- 2025-09-30: Debt Instrument, Repurchase AmountUSD (m); Debt Instrument, Interest Rate, Effective Percentagepure 2.10%; Debt Instrument, Interest Rate During Periodpure (m); Debt Instrument, Redemption Price, Percentagepure (m).
Coherus Oncology, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Debt Instrument, Repurchase Amount USD | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Interest Rate During Period pure | Debt Instrument, Redemption Price, Percentage pure | Convertible Notes Payable, Current USD | Long-term Debt USD | Debt Instrument, Fee Amount USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Long-term Debt, Fair Value USD | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Debt Instrument, Convertible, Threshold Trading Days item | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Notes Payable, Related Parties, Current USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | 2.10% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | 2.10% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | 3 month · 12.00% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | 2.10% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | 2.10% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-05-15 | $59.90M | (m) | (m) | 100.00% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | 2.10% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | 3 month · 12.60% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | 9 month · 13.30% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | 6 month · 13.30% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $27.12M |
| 2021-09-30 | (m) | (m) | (m) | (m) | $80.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | $80.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $80.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.63M |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.51M |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.40M |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.29M |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.18M |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $73.66M | (m) | (m) | $75.00M | (m) | (m) | (m) | $1.34M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $133.60M | (m) | (m) | (m) | (m) | (m) | (m) | $26.07M |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $73.29M | (m) | $133.60M | (m) | (m) | (m) | (m) | (m) | (m) | $25.97M |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $73.12M | (m) | $133.60M | (m) | (m) | (m) | (m) | (m) | (m) | $25.87M |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.77M |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.68M |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.58M |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.49M |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.40M |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.31M |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.23M |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.15M |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.06M |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $24.98M |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $24.91M |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $24.83M |
| 2016-02-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 15.00 | (m) | (m) | (m) |
| 2016-02-29 | (m) | (m) | (m) | (m) | (m) | (m) | $9.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $0.00 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $1.11M | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | $3.09M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |